Opko Health Inc

NASDAQ:OPK   3:25:15 PM EDT
4.33
+0.03 (+0.70%)
Regulatory, Earnings Announcements

Pfizer Announces Positive Phase 3 Top-Line Results For Once-Weekly Investigational LongActing Human Growth Hormone To Treat Children With Growth Hormone Deficiency

Published: 10/08/2020 11:06 GMT
OPKO Health Inc (OPK) - Pfizer Announces Positive Phase 3 Top-line Results for Once-weekly Investigational Long-acting Human Growth Hormone to Treat Children With Growth Hormone Deficiency.
Pfizer Inc - No Serious Adverse Events Were Reported in Phase 3 Trial.
Pfizer Inc - Study Met Its Primary Endpoint of Improved Treatment Burden Compared to Genotropin® (somatropin) for Injection Administered Once-daily.
Pfizer Inc - Phase 3 Trial Results Demonstrated Improved Treatment Burden With Once-weekly Injection.
Pfizer Inc - Key Secondary Endpoints Showed Overall Benefit in Treatment Experience With Somatrogon Once-weekly Dosing Regimen.
Pfizer Inc - Point Estimate of Treatment Difference Was in Favor of Somatrogon at Nominal 0.05 Level in Phase 3 Trial.
Pfizer - Top-line Results From Study Showed Treatment With Somatrogon Once-weekly Improved Mean Overall Life Interference Total Score After 12 Weeks.
Revenue is expected to be $374.36 Million
Adjusted EPS is expected to be $0.04

Next Quarter Revenue Guidance is expected to be $396.32 Million
Next Quarter EPS Guidance is expected to be $0.05

More details on our Analysts Page.